Ferrer finds ALS too tough to crack with oral edaravone

Privately-held Spanish drugmaker Ferrer has reported that the Phase III ADORE trial of oral edaravone formulation (FAB122) in amyotrophic lateral sclerosis (ALS) did not meet primary or key secondary endpoints.

The ADORE trial is a multicenter, multinational, double-blind, randomized, placebo-controlled study to investigate the efficacy and safety of 100mg edaravone once daily as an oral formulation in ALS patients, during a 48-week period.

"Our work to advance potentially transformative therapies in areas of high unmet need for people living with ALS will not stop"Study participants were randomized to receive oral edaravone or a placebo while continuing to receive their existing standard of care treatment for ALS.